Drug General Information (ID: DDIOZRL71I)
Drug Name			Mumps virus strain B level jeryl lynn live antigen		Drug Info		Tuberculin purified protein derivative		Drug Info
Drug Type		Vaccine				Allergenics
Therapeutic Class		Vaccine				Allergy Test

Mechanism of Mumps virus strain B level jeryl lynn live antigen-Tuberculin purified protein derivative Interaction (Severity Level: Moderate)
Diminish the response to diagnostic skin test antigens Click to Show/Hide Mechanism Graph
Drug Name		Mumps virus strain B level jeryl lynn live antigen				Tuberculin purified protein derivative
Mechanism		Vaccine or toxoid				Diagnostic skin test antigens
Key Mechanism Factor 1
		Factor Name		Diagnostic skin test antigens
		Factor Description		The efficacy of diagnostic skin test antigens may be reduced, leading to falsely insignificant or false-negative results may occur in such patients.
Mechanism Description		Reduced reactions to diagnostic skin test antigens for Tuberculin purified protein derivative when combined with Mumps virus strain B level jeryl lynn live antigen

Recommended Action
Management		Clinicians should be aware of the potential for falsely insignificant or false-negative results when performing delayed-hypersensitivity skin testing on patients who have recently received live virus vaccines. Diagnostic skin test antigens should be administered before, simultaneously with, or 4 to 6 weeks after immunization.

References
1	Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative). Connaught Laboratories Ltd, Toronto, ON.
2	Product Information. Multitest CMI (skin test antigens, multiple). Aventis Pharmaceuticals, Swiftwater, PA.
3	Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen). Aventis Pharmaceuticals, Swiftwater, PA.